Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 6/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865931 | 0.93 | CREBBP (0.35) | CREBBPEP300ICAM1SELENPC1 | |
| SCHEMBL13866018 | 0.87 | CREBBP (0.34) | CREBBPEP300MEN1KMT2ACFTR | |
| SCHEMBL13865937 | 0.85 | CREBBP (0.30) | CREBBP | |
| SCHEMBL13865938 | 0.79 | GYS1 (0.32) | CREBBPEP300MEN1KMT2A | |
| SCHEMBL13866028 | 0.79 | CREBBP (0.33) | CREBBPEP300ICAM1SELE | |
| SCHEMBL13866022 | 0.76 | EP300 (0.32) | CREBBPEP300 | |
| SCHEMBL14176074 | 0.76 | CREBBP (0.33) | CREBBPEP300 | |
| SCHEMBL13866066 | 0.75 | P2RX3 (0.32) | — | |
| SCHEMBL13865929 | 0.75 | CHEK1 (0.36) | MEN1KMT2AMRGPRX4 | |
| SCHEMBL13866043 | 0.75 | TP53 (0.33) | CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | CREBBP 1662/4885EP300 2892/4885MEN1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.